The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
Sepset said its early test for sepsis, a condition that requires rapid diagnosis and treatment, would give clinicians valuable time to identify treatment strategies.
The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.
In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.
British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.
DNAe said its semiconductor-based platform has potential to detect a broader variety of pathogens and resistance genes than current molecular technologies.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
